Details

Autor(en) / Beteiligte

• Pombo‐Suárez, Manuel
• Seoane‐Mato, Daniel
• Díaz‐González, Federico
• Cea‐Calvo, Luis
• Sánchez‐Alonso, Fernando
• Sánchez‐Jareño, Marta
• Jovani, Vega
• García‐Magallón, Blanca
• Martínez‐González, Olga
• Campos‐Fernández, Cristina
• Manero, Javier
• Díaz‐Torne, Cesar
• Bohórquez, Cristina
• Ros‐Vilamajó, Inmaculada
• Pérez‐Vera, Yanira
• Castrejón, Isabel

Titel

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Ist Teil von

• Musculoskeletal care, 2023-03, Vol.21 (1), p.189-197

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Aim To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors. Methods Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started golimumab >6 months before the analysis for an approved indication (rheumatoid arthritis [RA], axial spondyloarthritis [SpA] or psoriatic arthritis [PsA]). Results Among 885 patients (RA 267, axial SpA 370, PsA 248) receiving 944 cycles of golimumab, the retention rate of golimumab was 71.1% (95% confidence interval: 68.0–73.9) at year 1% and 37.7% (95% CI: 33.3–42.1) at year 7 and at year 8. Retention was higher when golimumab was used as the first biological drug (81.7% at year 1, 49.9% at year 7, p < 0.001). In Cox regression analysis, factors associated with golimumab retention included use as first‐line therapy (hazard ratio [HR] for discontinuation 1.52 for second‐ and 1.79 for third/later‐line vs. first‐line), use in axial SpA or PsA rather than RA (HR for axial SpA vs. RA 0.59, for PsA vs. Rheumatoid arthritis 0.67), and treatment with concomitant methotrexate (HR 0.67). Factors associated with golimumab discontinuation were corticosteroid use (HR 1.46) and disease activity above median (HR 1.29) at golimumab initiation. Conclusion Based on this retrospective analysis of the BIOBADASER registry, nearly two‐fifths (37.7%) of adult rheumatology patients initiating golimumab will remain on treatment for 8 years, with a higher probability of retention in axial SpA or PsA indications and when golimumab is used as first biologic.